| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INMB | Common Stock | Sale | -$110K | -10K | -10.85% | $11.01 | 82.2K | Jul 12, 2023 | See Footnote | F1, F2, F3 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 22, 2021. |
| F2 | The price reported in Column 4 is a weighted average price. These shares of common stock were sold in multiple transactions ranging from $11.00 to $11.10, inclusive. The reporting person undertakes to provide to Inmune Bio Inc., any security holder of Inmune Bio Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above. |
| F3 | These shares of common stock are held by CTI Holdings, a company of which Mr. Schroeder is the majority shareholder. Mr. Schroeder has voting and investment control over these shares. |